108 related articles for article (PubMed ID: 2389825)
1. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
3. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
[TBL] [Abstract][Full Text] [Related]
5. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies.
Marchette NJ; Dubois DR; Larsen LK; Summers PL; Kraiselburd EG; Gubler DJ; Eckels KH
Am J Trop Med Hyg; 1990 Aug; 43(2):212-8. PubMed ID: 1975159
[TBL] [Abstract][Full Text] [Related]
6. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
7. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
[TBL] [Abstract][Full Text] [Related]
8. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
Kraiselburd E; Kessler MJ; Torres-Blasini G
Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
[TBL] [Abstract][Full Text] [Related]
9. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.
Vaughn DW; Hoke CH; Yoksan S; LaChance R; Innis BL; Rice RM; Bhamarapravati N
Vaccine; 1996 Mar; 14(4):329-36. PubMed ID: 8744561
[TBL] [Abstract][Full Text] [Related]
10. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
11. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
Bancroft WH; Scott RM; Eckels KH; Hoke CH; Simms TE; Jesrani KD; Summers PL; Dubois DR; Tsoulos D; Russell PK
J Infect Dis; 1984 Jun; 149(6):1005-10. PubMed ID: 6376649
[TBL] [Abstract][Full Text] [Related]
12. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.
Eckels KH; Scott RM; Bancroft WH; Brown J; Dubois DR; Summers PL; Russell PK; Halstead SB
Am J Trop Med Hyg; 1984 Jul; 33(4):684-9. PubMed ID: 6476216
[TBL] [Abstract][Full Text] [Related]
13. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
15. Atypical antibody responses in dengue vaccine recipients.
Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
[TBL] [Abstract][Full Text] [Related]
16. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
[TBL] [Abstract][Full Text] [Related]
18. Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods.
Summers PL; Eckels KH; Dalrymple JM; Scott RM; Boyd VA
J Clin Microbiol; 1984 May; 19(5):651-9. PubMed ID: 6330164
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
[TBL] [Abstract][Full Text] [Related]
20. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
Kochel TJ; Raviprakash K; Hayes CG; Watts DM; Russell KL; Gozalo AS; Phillips IA; Ewing DF; Murphy GS; Porter KR
Vaccine; 2000 Jul; 18(27):3166-73. PubMed ID: 10856796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
